1区 · 医学
Article
作者: Eno, Marsha ; Mohammad, Khadijah A. ; Kudalkar, Shalley ; Wu, Simiao ; Hurst, Dow ; Zvonok, Nikolai ; Reggio, Patricia ; Papahatjis, Demetris P. ; Wood, JodiAnne T. ; Hohmann, Andrea G. ; Morales, Paula ; Mackie, Ken ; Benchama, Othman ; Schimpgen, Marion ; Xu, Shu ; Makriyannis, Alexandros ; Zhou, Han ; Li, Ai-Ling ; Honrao, Chandrashekhar ; Marnett, Lawrence J. ; Nikas, Spyros P. ; Liu, Yingpeng ; Ji, Lipin
The synthesis of potent metabolically stable endocannabinoids is challenging. Here we report a chiral arachidonoyl ethanolamide (AEA) analogue, namely, (13 S,1' R)-dimethylanandamide (AMG315, 3a), a high affinity ligand for the CB1 receptor ( Ki of 7.8 ± 1.4 nM) that behaves as a potent CB1 agonist in vitro (EC50 = 0.6 ± 0.2 nM). (13 S,1' R)-dimethylanandamide is the first potent AEA analogue with significant stability for all endocannabinoid hydrolyzing enzymes as well as the oxidative enzymes COX-2. When tested in vivo using the CFA-induced inflammatory pain model, 3a behaved as a more potent analgesic when compared to endogenous AEA or its hydrolytically stable analogue AM356. This novel analogue will serve as a very useful endocannabinoid probe.